Chemotherapy for low-grade bladder cancer that comes back
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether putting two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can treat low-grade bladder cancer that is at intermediate risk. The goal is to see if this approach can help people avoid more invasive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have low-grade bladder cancer that has come back, is larger than 3 cm, or is in more than one spot.
- Your cancer hasn't spread to the kidneys or ureters (tubes from kidneys to bladder).
- You haven't had BCG treatment before for bladder cancer.
- You have enough healthy blood cells (neutrophils and platelets) to safely receive chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
This trial tests if the drug dutasteride can help people with a slow-growing type of bladder cancer that hasn't spread into the muscle wall. It may be an option for those not receiving other standard treatments like BCG therapy or chemotherapy directly into the bladder.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.